Jonathan Baliff
Chief Financial Officer
You know, with CFO, we have been very explicit that we've invested, you know, over $65 million both obviously client investment funds which obviously, we deployed quite effectively in our own funds, but mostly client investment funds. So we've invested a significant amount of money to gain all of the relationships, the capability internally, and obviously, the results are starting to show. You don't go from, you know, an expectation that, you know, was pretty high dealing with sixteen Pillboxes to now twenty-eight. And beyond in these partnerships now, the new one with Bristol Myers, that doesn't happen by accident. And we're very measured when we talk about it, Suji, to you in the market because we are creating something that is both unique and can also significantly scale from a revenue and return on invested capital standpoint. We're very measured in how we talk about it, but we're very excited about the results, which were significantly higher than expectations. And I would go out to our social media sites, and you can see some talks and interviews given by Dr. Ken Sabin that I think could get a lot of additional data on that. But I think the part that we're particularly starting to emphasize now is that I think you mentioned we had previously talked heavily about was the fact that we are building our own IP here as we've spent a lot of time studying the drug development process. And leveraging our expertise to take a look at where we're gonna fit in and what are the opportunities for potential business models. And as we tried to articulate, it's developing the seed crystals in space that can operate as a seed that can then be replicated on Earth, so you don't have to do it all in space. You just bring down that critical intellectual property, that seed crystal down, which is very small. And because we've demonstrated that we can replicate it on Earth, we can now take those seed crystals as IP and partner with the next chain in the value chain of drug development. And that's where we're focused on taking this IP we're developing as part of flying the small molecules on our own is to have our own IP that we can partner with biopharma companies that are in the business of the full development life cycle, partner with them, providing this unique IP in exchange for some sort of royalty structure. Early days, no doubt, but this is super exciting to us because we get a lot of questions from people about where is all of this heading, and I think we have a clear path to a real potential business model here to leverage this now. Not a lot of more investment. I have to emphasize, not a lot more investment. Right? That's key. Right. It's really about now harvesting.